Tremfya And Taltz Provide PsA Highlights At EULAR
The spotlight was on anti-interleukin drugs at the Madrid meeting last week, especially their role in advancing the treatment of psoriatic arthritis.
You may also be interested in...
Novartis's Cosentyx Fails To EXCEED Humira in PsA
The Swiss major's immunology head tells Scrip that while Cosentyx was unable to beat Humira on the 20% improvement scale for symptoms in psoriatic arthritis patients, the totality of the data from the EXCEED study should sway clinicians to use the IL-17 inhibitor as a first-line treatment.
Keeping Track: A Duo Of RTOR Approvals, Thumbs Up For First Oral GLP-1 Treatment, And First Ebola Vaccine Nears US Market
The latest drug development news and highlights from our US FDA Performance Tracker.
Novartis MAXIMISEs Cosentyx PsA Position
Up to two thirds of patients with psoriatic arthritis experience inflammatory back pain and the Swiss major has presented data showing that its best-selling drug achieved rapid and significant improvements.